HATİCE BODUR
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Yıldırım Beyazıt University School of Medicine, Ankara, Turkey)
Fatma GÜL YURDAKUL
(Department of Physical Medicine and Rehabilitation, University of Health Sciences, Ankara Numune Training and Research Hospital, Ankara, Turkey)
ŞEBNEM ATAMAN
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey)
Yeşim GARİP
(Department of Physical Medicine and Rehabilitation, Ankara Numune Training and Research Hospital, Ankara, Turkey)
KEMAL NAS
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Sakarya University School of Medicine, Sakarya, Turkey)
Fikriye Figen AYHAN
(Department of Physical Medicine and Rehabilitation, Uşak University, High School of Health Sciences, Uşak, Turkey)
ÖZGÜR AKGÜL
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey)
AYŞEN AKINCI
(Department of Physical Medicine and Rehabilitation, Hacettepe University School of Medicine, Ankara, Turkey)
ZÜHAL ALTAY
(Department of Physical Medicine and Rehabilitation, İnönü University School of Medicine, Malatya, Turkey)
MURAT BİRTANE
(Department of Physical Medicine and Rehabilitation, Trakya University School of Medicine, Edirne, Turkey)
Derya SOY BUĞDAYCI
(Department of Physical Medicine and Rehabilitation, İstanbul Training and Research Hospital, İstanbul, Turkey)
Erhan ÇAPKIN
(Department of Physical Medicine and Rehabilitation, Karadeniz Technical University School of Medicine, Trabzon, Turkey)
REMZİ ÇEVİK
(Department of Physical Medicine and Rehabilitation, Dicle University School of Medicine, Diyarbakır, Turkey)
MEHMET TUNCAY DURUÖZ
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Marmara University School of Medicine, İstanbul, Turkey)
GÜLCAN GÜRER
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Adnan Menderes University School of Medicine, Aydın, Turkey)
CAHİT KAÇAR
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey)
AYHAN KAMANLI
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Sakarya University School of Medicine, Sakarya, Turkey)
Taciser KAYA
(Department of Physical Medicine and Rehabilitation, University of Health Sciences, İzmir Bozyaka Training and Research Hospital, İzmir, Turkey)
Hilal KOCABAŞ
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey)
ÖMER KURU
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ondokuz Mayıs University School of Medicine, Samsun, Turkey)
Ece KAPTANOĞLU
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Cumhuriyet University School of Medicine, Sivas, Turkey)
MELTEM ALKAN MELİKOĞLU
(Department of Physical Medicine and Rehabilitation, Medical Faculty of Atatürk University, Erzurum, Turkey)
Erhan ÖZDEMİREL
(Department of Rheumatology, SBÜ Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey)
Sumru ÖZEL
(Department of Physical Medicine and Rehabilitation, Hitit University School of Medicine, Çorum, Turkey)
AYLİN REZVANİ
(Department of Physical Medicine and Rehabilitation, Bezmiâlem Foundation University, İstanbul, Turkey)
İLHAN SEZER
(Department of Physical Medicine and Rehabilitation, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey)
İsmihan SUNAR
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey)
TUFAN GÜRKAN YILMAZ
(Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey)
Yıl: 2018Cilt: 33Sayı: 1ISSN: 2148-5046 / 2618-6500Sayfa Aralığı: 1 - 16İngilizce

156 1
Turkish League Against Rheumatism Consensus Report: Recommendations For Management of Axial Spondyloarthritis
Objectives: This study aims to update 2011 Turkish League Against Rheumatism SpondyloArthritis Recommendations, and to compose a national expert opinion on management of axial spondyloarthritis under guidance of current guidelines, and implantation and dissemination of these international guidelines into our clinical practice. Materials and methods: A scientific committee of 28 experts consisting of 14 rheumatologists and 14 physical medicine and rehabilitation specialists (one of them also has an immunology PhD) was formed. The recommendations, systematic reviews, and meta-analyses including pharmacologic and non-pharmacologic treatment were scrutinized paying special attention with convenient key words. The draft of Turkish League Against Rheumatism opinion whose roof consisted of international treatment recommendations, particularly the Assessment of SpondyloArthritis International Society/European League Against Rheumatism recommendations was composed. Assessment of level of agreement with opinions by task force members was established through the Delphi technique. Voting using a numerical rating scale assessed the strength of each recommendation. Results: Panel compromised on five basic principles and 13 recommendations including pharmacological and nonpharmacological methods. All of the recommendations had adequate strength. Conclusion: Turkish League Against Rheumatism expert opinion for the management of axial spondyloArthritis was developed based on scientific evidence. These recommendations will be updated regularly in accordance with current developments.
Fen > Tıp > Romatoloji
DergiAraştırma MakalesiErişime Açık
  • Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international crosssectional ASAS-COMOSPA study. Ann Rheum Dis 2016;75:1016-23.
  • Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 2017;47:183-92.
  • Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017;76:1070-7.
  • Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 2015;373:2534-48.
  • Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 2017;76:571-92.
  • Cheung PP. Anti-IL17A in Axial SpondyloarthritisWhere Are We At? Front Med (Lausanne) 2017;4:1.
  • Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 2017;47:343-50.
  • Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide nonmedical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017;76:1426-31.
  • Yu DT, Assessment and Treatment for Ankylosing Spondylitis in Adults- Biosimiliar for Infliximab. In: Sieper J, section editor. Avaliable from: https://www. uptodate.com/contents/search.
  • Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol 2016;12:282-95.
  • Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNF-a blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a metaanalysis. Ann Rheum Dis 2015;74:1241-8.
  • Ma Z, Liu X, Xu X, Jiang J, Zhou J, Wang J, et al. Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis. Medicine (Baltimore) 2017;96:7145.
  • Chen C, Zhang X, Xiao L, Zhang X, Ma X. Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis. Medicine (Baltimore) 2016;95:3060.
  • Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011;70:590-6.
  • Kılıç G, Özgöçmen S. Pharmacological management of ankylosing spondylitis. Turkiye Klinikleri J PM&RSpecial Topics 2014;7:35-43.
  • Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013;2:CD004524.
  • Bandinelli F, Scazzariello F, Pimenta da Fonseca E, Barreto Santiago M, Marcassa C, Nacci F, et al. Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability. Drug Des Devel Ther 2016;10:3717-3724.
  • Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 2014;73:243-6.
  • Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a metaanalysis of effectiveness and side effects. CMAJ 2006;174:1589-94.
  • Poddubnyy D, van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am 2012;38:601-11.
  • Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, et al. Efficiency of treatment with nonsteroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford) 2017;56:95-102.
  • Poddubnyy D, Rudwaleit M, Haibel H, Listing J, MärkerHermann E, Zeidler H, et al. Effect of non-steroidal antiinflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616-22.
  • Solomon DH. “Nonselective NSAID: Overview of aderverse effects” In: Furst DE, section editor. Avaliable from: https://www.uptodate.com/contents/search
  • Bodur H. Treatment of Early Axial Spondyloarthritis. Turkiye Klinikleri J PM&R-Special Topics 2014;7:9-15.
  • Millner JR, Barron JS, Beinke KM, Butterworth RH, Chasle BE, Dutton LJ, et al. Exercise for ankylosing spondylitis: An evidence-based consensus statement. Semin Arthritis Rheum 2016;45:411-27.
  • Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388-98.
  • Berdal G, Halvorsen S, van der Heijde D, Mowe M, Dagfinrud H. Restrictive pulmonary function is more prevalent in patients with ankylosing spondylitis than in matched population controls and is associated with impaired spinal mobility: a comparative study. Arthritis Res Ther 2012;14:19.
  • Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014;73:1455-61.
  • Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 2015;74:52-9.
  • Di Carlo M, Lato V, Di Matteo A, Carotti M, Salaffi F. Defining functioning categories in axial Spondyloarthritis: the role of the ASAS Health Index. Rheumatol Int 2017;37:713-8.
  • Landewé R, van Tubergen A. Clinical Tools to Assess and Monitor Spondyloarthritis. Curr Rheumatol Rep 2015;17:47.
  • Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68 Suppl 2:ii1-44.
  • Bergman M, Lundholm A. Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. Rheumatology 2018;57:419-28.
  • Reimold AM, Chandran V. Nonpharmacologic therapies in spondyloarthritis. Best Pract Res Clin Rheumatol 2014;28:779-92.
  • Danve A, Deodhar A. Treat to Target in Axial Spondyloarthritis: What Are the Issues? Curr Rheumatol Rep 2017;19:22.
  • Bodur H. The Fight Against Rheumatism is in its 70th Year. Arch Rheumatol 2017;32:1-2.
  • van der Horst-Bruinsma I, de Vries M, van den Bosch F. Spondyloarthritis: Treatment. In: Bijlsma JWJ, Hachulla E, editors EULAR Textbook on Rheumatic Disease. 2nd ed. London: BMJ; 2015. p. 319-43.
  • Rosenbaum J, Chandran V. Management of comorbidities in ankylosing spondylitis. Am J Med Sci 2012;343:364-6.
  • Bodur H, Sivas F, Yılmaz Ö, Özgöçmen S, Günaydın. R, Kaya T, et al. Turkish League against Rheumatism. National Recommendations for the management of ankylosing spondylitis. Turk J Rheumatol 2011;26:173-86.
  • Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 2017;76:948-59.
  • Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty 2017;32:2628-38.
  • Ozgocmen S, Akgul O, Altay Z, Altindag O, Baysal O, Calis M, et al. Expert opinion and key recommendations for the physical therapy and rehabilitation of patients with ankylosing spondylitis. Int J Rheum Dis 2012;15:229-38.
  • Zangi HA, Ndosi M, Adams J, Andersen L, Bode C, Boström C, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis 2015;74:954-62.
  • Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17-28.
  • Mandl P, Navarro-Compán V, Terslev L, Aegerter P, van der Heijde D, D’Agostino MA, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 2015;74:1327-39.
  • Rohekar S, Chan J, Tse SM, Haroon N, Chandran V, Bessette L, et al. 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. J Rheumatol 2015;42:665-81.
  • Rohekar S, Chan J, Tse SM, Haroon N, Chandran V, Bessette L, et al. 2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. J Rheumatol 2015;42:654-64.
  • Machado P, Cerqueira M, Ávila-Ribeiro P, Aguiar R, Bernardo A, Sepriano A, et al. Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis - 2016 update. Acta Reumatol Port 2017;42:209-18.
  • Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2016;68:282-98.
  • Wendling D, Lukas C, Paccou J, Claudepierre P, Carton L, Combe B, et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine 2014;81:6-14.
  • National Institute for Health and Care Excellence: Clinical Guidelines. Spondyloarthritis in Over 16s: Diagnosis and Management. London: NICE Guideline No 65; 2017.
  • Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3-17.
  • van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978-91.
  • van der Heijde D, Aletaha D, Carmona L, Edwards CJ, Kvien TK, Kouloumas M, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
  • Yu DT. Diagnosis and differential diagnosis of ankylosing spondylitis in adults. In: Sieper J, section editor. Avaliable from: https://www.uptodate.com/contents/search
  • Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017;390:73-84.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.